The B cell deficient and spleen tyrosine kinase (SYK) inhibitor-treated MRL/lpr mice were found not to develop spontaneous dermatitis [8, 43] and rituximab has been shown to have a therapeutic effect against cutaneous lesions in patients with SLE [44]. Here, SYK is linked to skin disorder.